Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00065325
Status:
COMPLETED
Last Update Posted:
2015-02-24
First Post:
2003-07-21
Brief Title:
The Evaluation of the Efficacy and Tolerability of FASLODEX Fulvestrant and AROMASIN Exemestane in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double Blind Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant FASLODEX vs Exemestane AROMASIN in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor AI Therapy
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EFECT
Brief Summary:
The purpose of this study is to compare the efficacy of Faslodex fulvestrant to Aromasin exemestane in hormone receptor positive postmenopausal women with advanced breast cancer Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient whichever occurs first
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EFECT | None | None | None |
| D6997C00048 | None | None | None |